Bevacizumab is an mAb that is specific for vascular endothelial growth factor A (VEGF-A) and has been labeled with IRDye800 for in vivo optical imaging to guide surgical resection of breast and pancreatic cancer (Table 1). Here, VEGFA is linked to pancreatic neoplasm.